TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States

Elizabeth Raymond, Erica Chong, Beverly Winikoff, Ingrida Platais, Meighan Mary, Tatyana Lotarevich, Philicia W. Castillo, Bliss Kaneshiro, Mary Tschann, Tiana Fontanilla, Maureen Baldwin, Ariela Schnyer, Leah Coplon, Nicole Mathieu, Paula Bednarek, Meghan Keady, Esther Priegue

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: To evaluate the safety, feasibility, and acceptability of a direct-to-patient telemedicine service that enabled people to obtain medical abortion without visiting an abortion provider in person. Study design: We offered the service in five states. Each participant had a videoconference with a study clinician and had pre-treatment laboratory tests and ultrasound at facilities of her choice. If the participant was eligible for medical abortion, the clinician sent a package containing mifepristone, misoprostol, and instructions to her by mail. After taking the medications, the participant obtained follow-up tests and had a follow-up consultation with the clinician by telephone or videoconference to evaluate abortion completeness. The analysis was descriptive. Results: Over 32 months, we conducted 433 study screenings and shipped 248 packages. The median interval between screening and mailing was 7 days (91st percentile 17 days), and no participant took the mifepristone at ≫71 days of gestation. We ascertained abortion outcomes of 190/248 package recipients (77%): 177/190 (93%) had complete abortion without a procedure. Of the 217/248 package recipients who provided meaningful follow-up data (88%), one was hospitalized for postoperative seizure and another for excessive bleeding, and 27 had other unscheduled clinical encounters, 12 of which resulted in no treatment. A total of 159/248 participants who received packages (64%) completed satisfaction questionnaires at study exit; all were satisfied with the service. Conclusions: This direct-to-patient telemedicine abortion service was safe, effective, efficient, and satisfactory. The model has the potential to increase abortion access by enhancing the reach of providers and by offering people a new option for obtaining care conveniently and privately. Implications: Provision of medical abortion by direct-to-patient telemedicine and mail has the potential to increase abortion access by increasing the reach of providers and by offering people the option of obtaining abortion care without an in-person visit to an abortion provider.

Original languageEnglish (US)
JournalContraception
DOIs
StatePublished - Jan 1 2019

Fingerprint

Telemedicine
Videoconferencing
Mifepristone
Postal Service
Misoprostol
Telephone
Seizures
Referral and Consultation
Hemorrhage
Safety
Pregnancy
Therapeutics

Keywords

  • Mail
  • Medical abortion
  • Telemedicine
  • United States

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

TelAbortion : evaluation of a direct to patient telemedicine abortion service in the United States. / Raymond, Elizabeth; Chong, Erica; Winikoff, Beverly; Platais, Ingrida; Mary, Meighan; Lotarevich, Tatyana; Castillo, Philicia W.; Kaneshiro, Bliss; Tschann, Mary; Fontanilla, Tiana; Baldwin, Maureen; Schnyer, Ariela; Coplon, Leah; Mathieu, Nicole; Bednarek, Paula; Keady, Meghan; Priegue, Esther.

In: Contraception, 01.01.2019.

Research output: Contribution to journalArticle

Raymond, E, Chong, E, Winikoff, B, Platais, I, Mary, M, Lotarevich, T, Castillo, PW, Kaneshiro, B, Tschann, M, Fontanilla, T, Baldwin, M, Schnyer, A, Coplon, L, Mathieu, N, Bednarek, P, Keady, M & Priegue, E 2019, 'TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States', Contraception. https://doi.org/10.1016/j.contraception.2019.05.013
Raymond, Elizabeth ; Chong, Erica ; Winikoff, Beverly ; Platais, Ingrida ; Mary, Meighan ; Lotarevich, Tatyana ; Castillo, Philicia W. ; Kaneshiro, Bliss ; Tschann, Mary ; Fontanilla, Tiana ; Baldwin, Maureen ; Schnyer, Ariela ; Coplon, Leah ; Mathieu, Nicole ; Bednarek, Paula ; Keady, Meghan ; Priegue, Esther. / TelAbortion : evaluation of a direct to patient telemedicine abortion service in the United States. In: Contraception. 2019.
@article{8d2cae5a6a74404893c5ab709917f6a8,
title = "TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States",
abstract = "Objectives: To evaluate the safety, feasibility, and acceptability of a direct-to-patient telemedicine service that enabled people to obtain medical abortion without visiting an abortion provider in person. Study design: We offered the service in five states. Each participant had a videoconference with a study clinician and had pre-treatment laboratory tests and ultrasound at facilities of her choice. If the participant was eligible for medical abortion, the clinician sent a package containing mifepristone, misoprostol, and instructions to her by mail. After taking the medications, the participant obtained follow-up tests and had a follow-up consultation with the clinician by telephone or videoconference to evaluate abortion completeness. The analysis was descriptive. Results: Over 32 months, we conducted 433 study screenings and shipped 248 packages. The median interval between screening and mailing was 7 days (91st percentile 17 days), and no participant took the mifepristone at ≫71 days of gestation. We ascertained abortion outcomes of 190/248 package recipients (77{\%}): 177/190 (93{\%}) had complete abortion without a procedure. Of the 217/248 package recipients who provided meaningful follow-up data (88{\%}), one was hospitalized for postoperative seizure and another for excessive bleeding, and 27 had other unscheduled clinical encounters, 12 of which resulted in no treatment. A total of 159/248 participants who received packages (64{\%}) completed satisfaction questionnaires at study exit; all were satisfied with the service. Conclusions: This direct-to-patient telemedicine abortion service was safe, effective, efficient, and satisfactory. The model has the potential to increase abortion access by enhancing the reach of providers and by offering people a new option for obtaining care conveniently and privately. Implications: Provision of medical abortion by direct-to-patient telemedicine and mail has the potential to increase abortion access by increasing the reach of providers and by offering people the option of obtaining abortion care without an in-person visit to an abortion provider.",
keywords = "Mail, Medical abortion, Telemedicine, United States",
author = "Elizabeth Raymond and Erica Chong and Beverly Winikoff and Ingrida Platais and Meighan Mary and Tatyana Lotarevich and Castillo, {Philicia W.} and Bliss Kaneshiro and Mary Tschann and Tiana Fontanilla and Maureen Baldwin and Ariela Schnyer and Leah Coplon and Nicole Mathieu and Paula Bednarek and Meghan Keady and Esther Priegue",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.contraception.2019.05.013",
language = "English (US)",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - TelAbortion

T2 - evaluation of a direct to patient telemedicine abortion service in the United States

AU - Raymond, Elizabeth

AU - Chong, Erica

AU - Winikoff, Beverly

AU - Platais, Ingrida

AU - Mary, Meighan

AU - Lotarevich, Tatyana

AU - Castillo, Philicia W.

AU - Kaneshiro, Bliss

AU - Tschann, Mary

AU - Fontanilla, Tiana

AU - Baldwin, Maureen

AU - Schnyer, Ariela

AU - Coplon, Leah

AU - Mathieu, Nicole

AU - Bednarek, Paula

AU - Keady, Meghan

AU - Priegue, Esther

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: To evaluate the safety, feasibility, and acceptability of a direct-to-patient telemedicine service that enabled people to obtain medical abortion without visiting an abortion provider in person. Study design: We offered the service in five states. Each participant had a videoconference with a study clinician and had pre-treatment laboratory tests and ultrasound at facilities of her choice. If the participant was eligible for medical abortion, the clinician sent a package containing mifepristone, misoprostol, and instructions to her by mail. After taking the medications, the participant obtained follow-up tests and had a follow-up consultation with the clinician by telephone or videoconference to evaluate abortion completeness. The analysis was descriptive. Results: Over 32 months, we conducted 433 study screenings and shipped 248 packages. The median interval between screening and mailing was 7 days (91st percentile 17 days), and no participant took the mifepristone at ≫71 days of gestation. We ascertained abortion outcomes of 190/248 package recipients (77%): 177/190 (93%) had complete abortion without a procedure. Of the 217/248 package recipients who provided meaningful follow-up data (88%), one was hospitalized for postoperative seizure and another for excessive bleeding, and 27 had other unscheduled clinical encounters, 12 of which resulted in no treatment. A total of 159/248 participants who received packages (64%) completed satisfaction questionnaires at study exit; all were satisfied with the service. Conclusions: This direct-to-patient telemedicine abortion service was safe, effective, efficient, and satisfactory. The model has the potential to increase abortion access by enhancing the reach of providers and by offering people a new option for obtaining care conveniently and privately. Implications: Provision of medical abortion by direct-to-patient telemedicine and mail has the potential to increase abortion access by increasing the reach of providers and by offering people the option of obtaining abortion care without an in-person visit to an abortion provider.

AB - Objectives: To evaluate the safety, feasibility, and acceptability of a direct-to-patient telemedicine service that enabled people to obtain medical abortion without visiting an abortion provider in person. Study design: We offered the service in five states. Each participant had a videoconference with a study clinician and had pre-treatment laboratory tests and ultrasound at facilities of her choice. If the participant was eligible for medical abortion, the clinician sent a package containing mifepristone, misoprostol, and instructions to her by mail. After taking the medications, the participant obtained follow-up tests and had a follow-up consultation with the clinician by telephone or videoconference to evaluate abortion completeness. The analysis was descriptive. Results: Over 32 months, we conducted 433 study screenings and shipped 248 packages. The median interval between screening and mailing was 7 days (91st percentile 17 days), and no participant took the mifepristone at ≫71 days of gestation. We ascertained abortion outcomes of 190/248 package recipients (77%): 177/190 (93%) had complete abortion without a procedure. Of the 217/248 package recipients who provided meaningful follow-up data (88%), one was hospitalized for postoperative seizure and another for excessive bleeding, and 27 had other unscheduled clinical encounters, 12 of which resulted in no treatment. A total of 159/248 participants who received packages (64%) completed satisfaction questionnaires at study exit; all were satisfied with the service. Conclusions: This direct-to-patient telemedicine abortion service was safe, effective, efficient, and satisfactory. The model has the potential to increase abortion access by enhancing the reach of providers and by offering people a new option for obtaining care conveniently and privately. Implications: Provision of medical abortion by direct-to-patient telemedicine and mail has the potential to increase abortion access by increasing the reach of providers and by offering people the option of obtaining abortion care without an in-person visit to an abortion provider.

KW - Mail

KW - Medical abortion

KW - Telemedicine

KW - United States

UR - http://www.scopus.com/inward/record.url?scp=85068028000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068028000&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2019.05.013

DO - 10.1016/j.contraception.2019.05.013

M3 - Article

C2 - 31170384

AN - SCOPUS:85068028000

JO - Contraception

JF - Contraception

SN - 0010-7824

ER -